Company profile: Crossbow Therapeutics
1.1 - Company Overview
Company description
- Provider of next-generation immunotherapies, including T-Bolt therapies that precisely target cancer cell antigens, and CBX-250, a T-cell engager for myeloid leukemia demonstrating potency and specificity in preclinical models.
Products and services
- CBX-250: A preclinical-grade T-cell engager for myeloid leukemia, demonstrating potency and specificity in preclinical models with targeted activity against disease-associated cells
- T-Bolt therapies: Custom-engineered next-generation immunotherapies that target cancer cell antigens with high precision to treat cancers with accurate antigen recognition
- Novel Cancer Treatment Development: Research-grade program that develops a new type of cancer treatment, creating next-generation immunotherapies precisely targeting cancer cell antigens
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Crossbow Therapeutics
MOMA Therapeutics
HQ: United States
Website
- Description: Provider of precision-medicine drug discovery targeting molecular machines involved in disease, enabled by a biomechanics engine integrating biochemistry, biophysics, structural biology, computation, chemistry, and functional genomics. Advancing precision oncology programs toward clinical trials and collaborating with Roche on a five-year effort to identify critical cancer dependencies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MOMA Therapeutics company profile →
2seventy bio
HQ: United States
Website
- Description: Provider of immuno-oncology cell therapies, discovering and developing cancer treatments, including ABECMA (idecabtagene vicleucel), a CAR T cell therapy for multiple myeloma developed in collaboration with Bristol Myers Squibb; leveraging expertise in cancer cell biology, genetics, and the immune response to advance its pipeline.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 2seventy bio company profile →
Portage Biotech
HQ: Canada
Website
- Description: Provider of early- to mid-stage oncology therapies, developing adenosine receptor inhibitors (PORT-6 A2A; PORT-7 A2B; PORT-8 dual A2A/A2B; PORT-9 A2B for colorectal/GI) and iNKT-engaging candidates (PORT-2 IMM60 liposomal for refractory NSCLC/melanoma; PORT-3 nanoparticle IMM60+NY-ESO-1). Products are advanced to clinical proof of concept and then sold or licensed for further development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Portage Biotech company profile →
Valitor Bio
HQ: United States
Website
- Description: Provider of novel methods to modify therapeutic proteins for control over pharmacological properties, including VLTR-559, a long-acting treatment for wet age-related macular degeneration designed to extend a single dose to six months or more; VLTR-557, a long-acting anti-VEGF biologic with potential six-month efficacy from one intravitreal injection; and Multivalent Polymer (MVP) Technology to enhance potency, durability, and safety.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Valitor Bio company profile →
Peptomyc
HQ: Spain
Website
- Description: Provider of next-generation cell-penetrating peptides targeting the Myc oncoprotein for cancer treatment. Built on Dr. Soucek’s Omomyc research, the company’s lead candidate, OMO-103, is an Omomyc-derived therapeutic peptide designed to inhibit the deregulated Myc oncoprotein in many cancers to halt tumor growth and progression. Founded in December 2014.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Peptomyc company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Crossbow Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Crossbow Therapeutics
2.2 - Growth funds investing in similar companies to Crossbow Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Crossbow Therapeutics
4.2 - Public trading comparable groups for Crossbow Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →